Pharma's global karma: Focus on Novartis, Pfizer and Ranbaxy

Author：

ISSN： 0258-0543

Source： Strategic Direction, Vol.22, Iss.1, 2006-01, pp. : 5-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pfizer takes a health check: Despite the drugs, giant firm feels the pressure

Strategic Direction, Vol. 20, Iss. 2, 2004-01 ,pp. : 10-12

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

New product introduction at TyRx Pharma, Inc.

By Amsbaugh Pamela Pitta Dennis A.

Journal of Product and Brand Management, Vol. 15, Iss. 7, 2006-12 ,pp. : 468-472

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

A different approach to innovation: How innovators at Pfizer and Nike ensure ideas come to fruition

Strategic Direction, Vol. 29, Iss. 7, 2013-06 ,pp. : 13-16

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

Focus on the dairy value chain

SourceOECD Industry, Services & Trade, Vol. 2011, Iss. 30, 2012-06 ,pp. : 89-113

OECD Publishing

Access to resources Recommend Favorite

Focus on the grain value chain

SourceOECD Industry, Services & Trade, Vol. 2011, Iss. 30, 2012-06 ,pp. : 66-88

OECD Publishing

Access to resources Recommend Favorite